S100A9 and Sepsis: This is because a swift increase in the level of IL-6 was observed during the early phase (1–5 days) of sepsis in both the wild-type and S100A9 knock-out mice, and treatment with anti-IL-6 neutralizing antibodies was very efficient at decreasing the expansion of MDSCs in the early septic phase only.